to eliminate tumor cells in the absence of therapeutic interventions. 4 To evaluate the relevance of the PD-1/PD-L1 pathway in HPV-HNSCC, we compared PD-1 expression by TILs and peripheral blood mononuclear cells (PBMCs) in patients with HPV-HNSCCs and from patients with a nonmalignant tonsil process. We found that the majority of activated CD8 + TILs isolated from HPV-HNSCC lesions express high levels of PD-1 as compared with CD8 + T cells isolated from benign, chronically inflamed tonsils.
The engagement of PD-1 on activated T cells by its ligand, PD-L1, can promote robust immunosuppressive effects. Therefore, we investigated the expression levels of PD-L1 in the tumor microenvironment and found that up to 70% of HPV-HNSCC cells expressed PD-L1 on their membrane, and that PD-L1 was often juxtaposed to CD8 + T cells. 4 In normal tissues, PD-L1 is induced in response to inflammatory cytokines such as interferon γ (IFNγ). This system constitutes a major mechanism of tissue protection in the course of T-cell mediated inflammation. Driven by these premises, we evaluated IFNγ expression in HPV-HNSCC lesions using quantitative RT-PCR. We found a significant increase in the expression of IFNγ-coding mRNAs, which correlated with increased amounts of CD8 The relevance of the PD-1:PD-L1 immune checkpoint in anticancer immunity is highlighted by several reports demonstrating that the blockade of PD-1 or PD-L1 by specific monoclonal antibodies can reverse the anergic state of tumorspecific T cells and hence enhance antitumor immune responses. 5, 6 The blockade human papillomavirus (hPV) variants associated with head and neck cancer generally induce a robust immune response. Despite the establishment of such an inflammatory microenvironment, hPV is able to persist and promote malignant transformation. the PD-1:PD-L1 immune checkpoint may play a critical role in the creation of an immunoprivileged site for viral persistence and the subsequent development of cancer.
with significant immune-related toxicities. 7 In a first-in-human clinical trial, a PD-1-blocking antibody (MDX-1106, Nivolumab) has been evaluated in patients affected by advanced metastatic melanoma, colorectal cancer, castrate-resistant prostate cancer, non-small-cell lung cancer, and renal cell carcinoma. In this study, the antibody was well tolerated and clinical activity was recorded in all settings but prostate cancer. 8 In a subset of patients, the expression of PD-L1 on the surface of tumor cells appeared to correlate with the likelihood of response to therapy. Extended Phase I clinical studies with anti-PD-1 (MDX-1106, Nivolumab) and anti-PD-L1 (BMS-936559) antibodies confirmed objective clinical responses in patients affected by multiple tumor types as well as a link between PD-L1 expression on the tumor cell surface and the rate of objective responses. 9, 10 As HPV-HNSCC cells express high levels of PD-L1 on their membrane, our study supports a rationale for administering PD-1-or PD-L1-targeting therapies to head and neck cancer patients (Fig. 1) .
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